The establishment of dendritic cell-tumor fusion vaccines for hormone refractory prostate cancer cell

Korean Journal of Urology

Volumn 51, Issue 2, 2010, Pages 139-144

  Kim, Tae Beom ^a   Park, Ho Ki ^a   Chang, Joo Hyun ^a   Choi, In Ho ^a   Kim, Khae Hawn ^a   Yoon, Sang Jin ^a   Lee, Min Sung ^a   Jung, Han ^a   Kim, Choung Soo ^b  

^a Gachon University College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

Cancer vaccines; Dendritic cells; Prostatic neoplasms

Indexed keywords

FUSION VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR LYSATE VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FETAL CALF SERUM; FLUORESCENCE ACTIVATED CELL SORTING; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; HUMAN CELL; MONOCYTE; PROSTATE CANCER; T LYMPHOCYTE;

EID: 77149164109     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.2.139     Document Type: Article

References (18)

1. Ha HK, Yun CJ, Lee SS, Shin DG, Lee W, Lee ZZ, et al. Survival rates and related factors in men with hormone-refractory prostate cancer. Korean J Urol 2009;50:649-55.
2. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
4. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
5. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998;14:551-60.
6. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
7. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594-600.
8. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
9. Segel LA, Jäger E, Elias D, Cohen IR. A quantitative model of autoimmune disease and T-cell vaccination: does more mean less? Immunol Today 1995;16:80-4.
10. Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ. Dendritic cell based therapy of cancer. Adv Exp Med Biol 1997;417:551-69.
11. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
12. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002;51:299-310.
13. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-203.
14. Banchereau J, Steinman RM. Dendritic cells and the control immunity. Nature 1998;392:245-52.
15. Reid CD, Stackpoole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+progenitors in human bone marrow. J Immunol 1992;149:2681-8.
16. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, et al. CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 1996;184:695-706.
17. Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 2000;1500:265-79.
18. Lundqvist A, Palmborg A, Bidla G, Whelan M, Pandha H, Pisa P. Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med Oncol 2004;21:155-65.